– Wearable sensors strongly correlated with clinical scales on motor impairment – – bioMUSE Study Validates Use of Wearable Sensors for Alterity’s Ongoing Phase 2 Clinical Trial – Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced a poster from ...
Regulatory Authorization Granted to Proceed with ATH434 Phase 2 Clinical Trial Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to allow evaluation ...
XBRL 30 June 2022 filed with the SEC
Second region now open for enrolment for rare, rapidly progressive, neurodegenerative disease MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 25 August 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company’s Phase 2 clinical trial of ATH434 for ...
Phase 2 clinical trial for ATH434 commences in New Zealand and patient enrolment begins Regulatory approval from the U.K. and Italian regulatory agencies to proceed with the Phase 2 trial A$4.1 million R&D Tax Incentive Scheme refund Cash balance on 30 June 2022 of A$34.8M MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 22 July 2022. ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first patient has been dosed in the Company’s Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder. While it is similar ...
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received a A$4.1 million cash refund from the Australian Taxation Office under the Australian Government’s R&D Tax Incentive Scheme. The cash refund relates to the cost of ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the Italian Medicines Agency, or Agenzia Italiana del Farmaco (AIFA), has authorized Alterity to conduct its Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will present at the VirtualInvestorConferences.com Life Sciences Investor Forum on Thursday, 23 June 2022 at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time. ...
Receive news from Alterity Therapeutics
